To view PDF documents, you must have Adobe Reader installed on your computer.

SINGULAIR is indicated for prophylaxis and chronic treatment of asthma in patients aged 12 months and older and for prevention of exercise-induced bronchoconstriction (EIB) in patients aged 15 years and older.

Important Information

SINGULAIR should not be used as rescue medication to treat acute asthma episodes. Patients should be advised to have appropriate rescue medication available.

Use of SINGULAIR may not eliminate the need for inhaled or systemic corticosteroids. Patients should not decrease the dose or stop taking any other anti-asthma medications unless instructed by a physician.

Safety and effectiveness of SINGULAIR in patients younger than 12 months with asthma have not been established.

For prevention of EIB, a single dose of SINGULAIR should be taken at least 2 hours before exercise. An additional dose of SINGULAIR should not be taken within 24 hours of a previous dose.

Patients already taking 1 tablet daily for another indication should not take an additional dose to prevent EIB. All patients should have available for rescue a short-acting ß-agonist.

Chronic daily administration of SINGULAIR for other indications has not been established to prevent acute episodes of EIB.

Patients with known aspirin sensitivity should continue avoidance of aspirin or nonsteroidal antiinflammatory agents while taking SINGULAIR.

Safety and effectiveness of SINGULAIR for EIB in patients younger than 15 years have not been established.

Before prescribing SINGULAIR, please read the Prescribing Information.

See all references.

This site is intended only for health care professionals of the United States, its territories, and Puerto Rico.

For general information and other services for physicians

SINGULAIR, Merck OnCall, and MerckServices are registered trademarks of Merck & Co., Inc.